Share page on LinkedIn

Biotech and early engagement considerations

What companies must consider when developing an asset

Whitepaper

Learn how to navigate the complexities of developing an asset and considering a drug development partner.

Emerging biotech companies are a significant and burgeoning sector of the pharmaceutical development market. These companies often require unique and specialised expertise to guide them through asset development.

There are a multitude of considerations when evaluating an asset for development, including the vision for the asset, development and continuum capabilities, and global versus local development. This paper is the first in a series of installments on asset development. The goal of this paper is to navigate the complexities of developing an asset and considering a drug development partner. Additional installments will discuss regulatory considerations, early development considerations, drug development considerations, Chemistry, Manufacturing, and Controls (CMC), and global versus local considerations.